<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04999800</url>
  </required_header>
  <id_info>
    <org_study_id>NCT20217</org_study_id>
    <nct_id>NCT04999800</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1</brief_title>
  <official_title>A Prospective Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Combined With Anlotinib in First-line Treatment for Patients With of R/M HNSCC PD-L1 CPS≥1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shi Yuankai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is main evaluate the efficacy and safety of Pembrolizumab combined with Anlotinib&#xD;
      in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma&#xD;
      with CPS≥1&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This test is a single-center, prospective phase II clinical research, plan included in 20&#xD;
      cases of eligible subjects, assessment in China PD-L1 CPS≥1 or more recurrent and/or&#xD;
      metastatic head and neck squamous cell carcinoma patients, Pembrolizumab combined with&#xD;
      Anlotinib for the initial curative effect, adverse reaction and safety, provide the basis for&#xD;
      subsequent clinical trials&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 18, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Pembrolizumab combined with Anlotinib</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rates(ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate objective response rates of first-line Pembrolizumab combined with Anlotinib in Chinese patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS≥1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease control rate(DCR)</measure>
    <time_frame>3 year</time_frame>
    <description>To evaluate other efficacy indicators of first-line Pembrolizumab combined with Anlotinib in Chinese patients with recurrent and/or metastatic head and neck squamous cell carcinoma with PD-L1 CPS≥1, including disease control rate(DCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response(DOR)</measure>
    <time_frame>3 year</time_frame>
    <description>To evaluate other efficacy indicators of first-line Pembrolizumab combined with Anlotinib in Chinese patients with recurrent and/or metastatic head and neck squamous cell carcinoma with PD-L1 CPS≥1, duration of response(DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival(PFS)</measure>
    <time_frame>3 year</time_frame>
    <description>To evaluate other efficacy indicators of first-line Pembrolizumab combined with Anlotinib in Chinese patients with recurrent and/or metastatic head and neck squamous cell carcinoma with PD-L1 CPS≥1, progression-free survival(PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>5 year</time_frame>
    <description>To evaluate other efficacy indicators of first-line Pembrolizumab combined with Anlotinib in Chinese patients with recurrent and/or metastatic head and neck squamous cell carcinoma with PD-L1 CPS≥1, overall survival (OS)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>tumor mutation burden（TMB）</measure>
    <time_frame>3 year</time_frame>
    <description>Correlation results of tumor mutation burden（TMB）</description>
  </other_outcome>
  <other_outcome>
    <measure>T cell gene expression</measure>
    <time_frame>3 year</time_frame>
    <description>Correlation results of T cell gene expression</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab combined with Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anlotinib 12 mg QD p.o for 2 weeks and then stop for 1 week, combined with Pembrolizumab 200 mg iv on day 1, and every 21 days is a treatment cycle until the disease progresses or the toxicity cannot be tolerated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, an stomach cancer</description>
    <arm_group_label>Pembrolizumab combined with Anlotinib</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>Anlotinib is an oral small molecule multi-target receptor tyrosine kinase inhibitor</description>
    <arm_group_label>Pembrolizumab combined with Anlotinib</arm_group_label>
    <other_name>AL3818</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Voluntarily sign written informed consent before screening; 2) Age ≥18 years old;&#xD;
             3) ECOG physical status score 0-1; 4) Histologically or cytologically confirmed&#xD;
             squamous cell carcinoma of the head and neck (HNSCC) with primary site of oral cavity,&#xD;
             oropharynx, hypopharynx or larynx; 5) Recurrent and/or metastatic HNSCC without&#xD;
             indications of local radical treatment; 6) According to the efficacy evaluation&#xD;
             criteria for solid tumors (RECIST version 1.1), at least one measurable lesion can be&#xD;
             selected as the target lesion after receiving previous radiotherapy only if there has&#xD;
             been definite disease progression 3 months after the end of radiotherapy; 7)&#xD;
             Sufficient tumor tissue samples for PD-L1 immunohistochemical detection; 8) Expected&#xD;
             survival of more than 3 months; 9) The main organs function normally, that is, they&#xD;
             meet the following criteria: I. Blood routine (no blood transfusion, erythropoietin&#xD;
             (EPO), granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage&#xD;
             colony-stimulating factor (GM-CSF) treatment within 14 days before screening&#xD;
             examination) : neutrophils ≥1.5× L09 /L, platelets ≥100×109/L, hemoglobin ≥90g/L; II.&#xD;
             Liver function: ALT and AST, ALT and AST≤3×ULN in patients without liver metastasis,&#xD;
             ALT and AST≤5×ULN in patients with liver metastasis;Total bilirubin (TBil) ≤1.5×ULN&#xD;
             (Gilbert syndrome patients, ≤3 ×ULN); Iii. Renal function: Serum creatinine (CR)&#xD;
             ≤1.5×ULN or creatinine clearance (CCR) ≥50ml/ min (subjects receiving carboplatin) or&#xD;
             ≥60ml/ min (subjects receiving cisplatin); IV. Coagulation function: APTT, INR, PT&#xD;
             ≤1.5×ULN; V. Echocardiography: left ventricular ejection fraction (LVEF) ≥50%; 10)&#xD;
             Women should agree to use contraceptives (such as intrauterine devices [IUDs],&#xD;
             contraceptives or condoms) during the study period and for 6 months after the end of&#xD;
             the study;Negative blood pregnancy test within 7 days prior to study enrolment and&#xD;
             must be non-lactating;Men should agree to use contraception during the study period&#xD;
             and within 6 months after the end of the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) The patient had necrotic lesions and was judged by the investigator to be at risk&#xD;
             of massive bleeding; 2) A history of hypersensitivity to amlotinib or pabrizumab or&#xD;
             any excipients; 3) Previous use of antiangiogenic drugs (such as amlotinib, apatinib,&#xD;
             bevacizumab, Endox, etc.); 4) The patient is using (or cannot be discontinued within 1&#xD;
             week prior to the first dosing of the study treatment) a Chinese herbal medicine&#xD;
             indicated for antitumor use; 5) poorly controlled pleural effusion, pericardial&#xD;
             effusion or ascites requiring frequent drainage;Patients with indwelling catheters&#xD;
             (such as the Pleurx ® catheter) are allowed to participate; 6) At the beginning of&#xD;
             study treatment, there was still an uncured toxic reaction from previous treatment and&#xD;
             CTCAE 5.0 was higher than level 1 (except for alopecia); 7) Spinal cord compression or&#xD;
             symptomatic untreated brain or spinal cord metastases (except asymptomatic, stable&#xD;
             condition, and no need for steroid therapy for 4 weeks prior to study treatment); 8)&#xD;
             poorly controlled tumor-related pain.Patients who require analgesics must receive a&#xD;
             steady dose before entering the study.Symptomatic lesions suitable for palliative&#xD;
             radiotherapy (e.g., bone metastases or metastases leading to nerve damage) should be&#xD;
             treated before enrolment.Prior to enrolment, local-regional treatment of asymptomatic&#xD;
             metastatic lesions with further growth that may result in functional deficits or&#xD;
             intractable pain (e.g., epidural metastases currently not associated with spinal cord&#xD;
             compression) should be considered, if appropriate.&#xD;
&#xD;
             9) Hepatitis B, hepatitis C or human immunodeficiency virus (HIV antibody&#xD;
             positive).Patients with positive hepatitis B antibodies were only eligible to&#xD;
             participate in the study if they had HBV DNA ˂2000cps/ml.Patients with hepatitis C&#xD;
             antibody positive were eligible to participate in the study only if polymerase chain&#xD;
             reaction showed HCV RNA negative; 10) Randomization of malignancies other than&#xD;
             advanced head and neck squamous cell carcinoma with negligible risk of metastasis or&#xD;
             death and expected radical outcome after treatment within the first 5 years&#xD;
             (e.g.,Adequately treated carcinoma in situ of the cervix, basal or squamous cell skin&#xD;
             cancer, localized prostate cancer for radical treatment, and ductal carcinoma in situ&#xD;
             for radical surgery); 11) Had major surgery other than a diagnosis of advanced head&#xD;
             and neck squamous cell carcinoma within 28 days prior to randomization or was expected&#xD;
             to require major surgery during the study period; 12) patients who have had previous&#xD;
             bone marrow transplantation or previous solid organ transplantation; 13) Any live&#xD;
             vaccine (for example, vaccines against infectious diseases, such as influenza,&#xD;
             varicella, etc.) was given within the first 4 weeks (28 days) of randomization; 14)&#xD;
             any factors that may affect the patient's oral administration, such as inability to&#xD;
             swallow, post-gastrointestinal resection, chronic diarrhea, and intestinal&#xD;
             obstruction; 15) Meets any of the following cardiac criteria: mean corrected QT&#xD;
             interval (QTc) from an electrocardiogram (ECG) in the resting state;470 msec (for the&#xD;
             first anomaly, the test was retest once within 48 h, calculated based on the average&#xD;
             result of two times).A variety of clinically significant cardiac rhythm, conduction,&#xD;
             and resting ECG abnormalities, such as complete left bundle branch block, degree III,&#xD;
             degree II, PR interval &amp;gt;250 msec.Various factors that may increase the risk of&#xD;
             prolonged QTC or arrhythmic events, such as coronary heart disease, heart failure,&#xD;
             hypokalemia, congenital long QT syndrome, a family history of first-degree relative&#xD;
             with long QT syndrome or sudden unexplained death under age 40, and being on any known&#xD;
             medication for prolonged QT; 16) Patients with any severe and/or uncontrolled disease,&#xD;
             including but not limited to: patients with poor blood pressure control (systolic &gt;&#xD;
             150 mmHg, diastolic &gt; 100 mmHg);Suffer from myocardial ischemia or myocardial&#xD;
             infarction, arrhythmias (including QTc ≥440ms) and congestive heart failure (New York&#xD;
             Heart Association (NYHA) grade) of grade I or above;Active or uncontrolled severe&#xD;
             infection (≥CTC AE grade 2 infection);Cirrhosis, decompensated liver disease;Renal&#xD;
             failure requires hemodialysis or peritoneal dialysis;Poor diabetes control (fasting&#xD;
             blood glucose (FBG) &gt; 10mmol/L);Routine urine indicated urinary protein ≥++, and&#xD;
             confirmed 24-hour urinary protein quantitative &gt; 1.0 g; 17) Patients with epileptic&#xD;
             seizures requiring treatment, with a history of psychotropic substance abuse and&#xD;
             unable to quit or with mental disorders; 18) Previous history of interstitial lung&#xD;
             disease, drug-induced interstitial lung disease, radiation pneumonia requiring steroid&#xD;
             treatment, and clinically evidenced active interstitial lung disease; 19) thrombotic&#xD;
             or embolic venous or arterial events, such as cerebrovascular accidents, including&#xD;
             transient ischemic attack, arterial thrombosis, deep vein thrombosis and pulmonary&#xD;
             embolism, occurred within 6 months before enrollment;Has a history of hemorrhagic&#xD;
             disease or abnormal blood clotting.&#xD;
&#xD;
             20) Lactating female patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute/Hospital, Chinese Academy of Medical Sciences&amp;Peking Union Medical college</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuankai Shi, MD</last_name>
    <phone>+86-10-87788293</phone>
    <email>syuankaipumc@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuankai Shi, MD</last_name>
      <phone>+86-10-87788293</phone>
      <email>syuankaipumc@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Shi Yuankai</investigator_full_name>
    <investigator_title>Director, Head of Oncology, Chief physician</investigator_title>
  </responsible_party>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>immune therapy</keyword>
  <keyword>Pembrolizumab combined with Anlotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

